Add BrightSurf on Google Email

Weill Cornell Medicine


New tool quantifies cancer’s ability to shape-shift

A new analytical tool called PATH can quantify tumor cell plasticity, which is a key characteristic of cancer that leads to treatment resistance and metastatic spread. Researchers used PATH to analyze tumor samples from animal models and human patients, revealing new details of how tumors exploit plasticity to spread.

SourceWeill Cornell Medicine·JournalNature Genetics·DateSep 24, 2024

New prostate biopsy technique lowers infection risk

A new prostate biopsy technique, transperineal biopsy, has been shown to lower the risk of infection compared to traditional biopsies. The PREVENT trial found no infections among men who underwent the transperineal procedure, while those with traditional transrectal biopsies had a 1.6% infection rate despite receiving antibiotics.

SourceWeill Cornell Medicine·JournalJAMA Oncology·DateSep 19, 2024

Large study confirms significant frequency of undetected responsiveness in severe brain injury

A recent study published in the New England Journal of Medicine found that one-fourth of patients in a coma or vegetative state showed clear signs of cognitive function on brain scans despite being unable to move or speak. This significant frequency of undetected responsiveness suggests that many seemingly unconscious patients may be a...

SourceWeill Cornell Medicine·JournalNew England Journal of Medicine·DateAug 14, 2024

A new use for propofol in treating epilepsy?

A study published in Nature found that propofol can restore the function of mutated HCN1 ion channels, which are associated with certain types of epilepsy. The researchers suggest using propofol to treat these conditions or designing new compounds with similar effects but reduced side effects.

SourceWeill Cornell Medicine·JournalNature·DateJul 31, 2024

Study backs RSV vaccine safety during pregnancy

A study published in JAMA Network Open found no association between RSV vaccination during late pregnancy and increased risk of preterm birth or poor outcomes. The research provides real-world evidence supporting the safety of Pfizer's Abrysvo vaccine, offering reassurance to patients and clinicians.

SourceWeill Cornell Medicine·JournalJAMA Network Open·DateJul 8, 2024

Putting the brakes on chronic inflammation

Researchers at Weill Cornell Medicine discovered that interleukin-23 acts on group 3 innate lymphoid cells to balance pro-inflammatory effects and maintain gut health. This interaction is impaired in chronic inflammatory bowel diseases, providing new insights into the disease and potential therapeutic targets.

SourceWeill Cornell Medicine·JournalNature·DateJun 12, 2024

Haiti study suggests early-onset heart failure is prevalent form of heart disease in low-income countries

A Weill Cornell Medicine study found that over 15-fold more Haitians have early-onset heart failure than previously thought, with elevated blood pressure being the leading risk factor. The research suggests a shift in focus to early prevention and treatment of cardiovascular diseases in low-income countries.

SourceWeill Cornell Medicine·JournalThe Lancet Regional Health - Americas·DateApr 29, 2024

Gut microbiota acts like an auxiliary liver

A new study reveals that gut microbiota significantly impacts host amino acid and glucose metabolism, leading to a second liver-like function. The research identifies specific bacterial metabolic genes responsible for depleting amino acids, which can be targeted to treat conditions such as type 2 diabetes and inflammatory bowel disease.

SourceWeill Cornell Medicine·JournalCell Host & Microbe·DateApr 23, 2024

Tracking a protein’s fleeting shape changes

Researchers developed a powerful new technique to generate dynamic structural data of proteins. They applied it to Glt Ph, revealing previously unseen structural states and uncovering the basis of wanderlust kinetics. The approach opens up possibilities to track protein structure in real-time.

SourceWeill Cornell Medicine·JournalNature Structural & Molecular Biology·DateApr 17, 2024

Clinical trial finds nasal spray safely treats recurrent abnormal heart rhythms

A clinical trial found that a nasal spray called etripamil effectively and safely treated recurrent episodes of paroxysmal supraventricular tachycardia (PSVT) in patients. The study showed that two-thirds of participants experienced relief within an hour, with an average time needed for symptom relief being 17 minutes.

SourceWeill Cornell Medicine·JournalJournal of the American College of Cardiology·DateApr 9, 2024